Status:
ACTIVE_NOT_RECRUITING
A Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy
Lead Sponsor:
Shandong Suncadia Medicine Co., Ltd.
Conditions:
Obstructive Hypertrophic Cardiomyopathy
Eligibility:
All Genders
18-85 years
Phase:
PHASE2
Brief Summary
The study is being conducted to evaluate the efficacy, and safety of HRS-1893 for obstructive hypertrophic cardiomyopathy
Eligibility Criteria
Inclusion
- Age 18-85 years old, gender unlimited;
- The diagnosis was obstructive hypertrophic cardiomyopathy.
- Echocardiographic laboratory tests showed LVEF≥60%;
- No previous left ventricular systolic dysfunction at any time (LVEF \< 45%);
- Understand the study procedure and sign the informed consent in person, willing to strictly follow the clinical study protocol to complete the study.
Exclusion
- Known or suspected invasive, genetic or storage diseases (e.g. Noonan syndrome, Fabre's disease, amyloidosis) that cause cardiac hypertrophy (similar to oHCM);
- Previous left ventricular systolic dysfunction at any time in the clinical course (LVEF \< 45%);
- Previous history of aortic stenosis or subaortic fixed stenosis;
Key Trial Info
Start Date :
August 11 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2025
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT06516068
Start Date
August 11 2024
End Date
August 1 2025
Last Update
July 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fuwai Hospital Chinese Academy of Medical Sciences (CAMS)
Beijing, Beijing Municipality, China, 100032